Skip to main content

Table 1 Patient Characteristics: Frontline Treatment with R-CVP and R-CHOP

From: R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature

Variable
(N; %)
R-CHOP
N = 223
Hiddemann et al [5]
R-CVP
N = 162
Marcus et al [7]
Total
N = 385
P-value
Sex M:88; 39.5%
F: 135; 60.5%
M: 88; 54.3%
F: 74; 45.7%
M: 176; 45.7%
F: 209; 54.3%
.004
Age>60 82; 36.8% 41; 25.3% 123; 31.9% .017
ECOG>1 16; 7.2% 4;2.5% 20; 5.2% .040
B-symptoms 80; 35.9% 65; 40.1% 145; 37.7% .396
Marrow involvement 136; 61.0% 103; 63.6% 239; 62.1% .605
IPI> 2 42; 18.8% 21; 13.0% 63; 16.4% .212
Stage I/II: 0; 0%
III/IV: 223; 100%
I/II: 2; 1.2%
III/IV: 160; 98.8%
I/II: 2; 0.5%
III/IV: 383; 99.5%
.342
Elevetaed LDH 51; 22.9% 39; 24.1% 90; 23.4% .783